GeneOne Life Science KRX:011000KOSPI
진원생명과학 · Korean news coverage and regulatory filings, organized.
Articles, 24h2
Articles, 7 days5
DART filings, 7 days2
Articles tracked15since Sep 11
In Q2 2026, GeneOne Life Science reported revenue of ₩2.1bn, down 69.8% year on year, and an operating loss of ₩12.8bn. GeneOne Life Science (진원생명과학) appeared in 5 Korean news articles and 2 DART filings over the past seven days. Coverage peaked on Oct 23 with 4 articles. The most common catalyst was risk & warnings (1).
Filing signals 4 quarters of losses Litigation Screener
GeneOne Life Science quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩2.1bn | -69.8% | −₩12.8bn | −₩18.9bn |
| Q1 2026 | ₩2.6bn | -69.6% | −₩2.3bn margin −90.8% | −₩2.4bn |
| Q4 2025 derived | ₩2.7bn | -74.8% | −₩13.1bn | −₩16.1bn |
| Q3 2025 | ₩5.1bn | -42.9% | −₩11.7bn margin −229.7% | −₩11.5bn |
| Q2 2025 | ₩6.8bn | -26.7% | −₩10.2bn margin −149.5% | −₩15.4bn |
| Q1 2025 | ₩8.5bn | +20.9% | −₩9.1bn margin −106.6% | −₩8.8bn |
| Q4 2024 derived | ₩10.5bn | -17.6% | −₩9.9bn margin −93.9% | −₩15.6bn |
| Q3 2024 | ₩8.9bn | -24.2% | −₩10.4bn margin −116.7% | −₩10.6bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
GeneOne Life Science top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest GeneOne Life Science news Korean headlines
-
진원생명과학, 美 이노비오와 소송서 1065억원 배상 판결
2 more on this story · 2 outlets
- 진원생명과학, 美 이노비오와 소송서 1065억원 배상 판결이데일리증권 · Oct 21 19:36
- 진원생명과학, 美 이노비오와 소송서 1065억원 배상 판결이데일리 · Oct 21 19:36